National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-CD19 fully human monoclonal antibody MDX-1342
A fully human anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential antineoplastic activity. Anti-CD19 monoclonal antibody MDX-1342 binds to CD19, depleting and eliminating CD19-expressing B-cells. CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:MDX-1342



Previous:anthracycline analogue GPX-150, anti-1-amino-3-[18F ]fluorocyclobutane-1-carboxylic acid, anti-B4 blocked ricin immunotoxin, anti-CCL-2 human monoclonal antibody CNTO 888, anti-CD137 monoclonal antibody
Next:anti-CD19-DM4 immunoconjugate SAR3419, anti-CD20 monoclonal antibody AME-133v, anti-CD20 monoclonal antibody R7159, anti-CD200 monoclonal antibody ALXN6000, anti-CD22 immunotoxin CAT-8015

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov